Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Abstract Damoctocog alfa pegol (BAY 94-9027, Jivi®), is a site-specifically PEGylated, extended half-life recombinant factor VIII (FVIII) that is approved in several European and non-European countries for on-demand treatment and prophylaxis of bleeding in previously treated patients aged ≥ 12 year...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark T. Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H. Poulsen, Karina Meijer, Mindy Simpson, Maria Elisa Mancuso
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-08-01
Series:Drugs in R&D
Online Access:https://doi.org/10.1007/s40268-024-00481-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40268-024-00481-7

Similar Items